Connect Biopharmaceuticals
Taicang
About Connect Biopharmaceuticals
Connect Biopharmaceuticals is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. They identify and advance our drug candidates through in-house discovery and in-licensing while leveraging qualified CROs for further development. The company successfully completed a phase I clinical trial study on our leading program CBP-307, a novel and selective second-generation S1P1 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease, and psoriasis. Connect Biopharmaceuticals currently conducting two phases 2 clinical studies in patients with ulcerative colitis and Crohn's disease with their lead drug candidate CBP-307. It also concluding a phase 1 study of our second drug candidate CBP-201 in healthy subjects, with a phase 1b study in atopic dermatitis patients expected to commence in Q1, 2019. Connect Biopharmaceuticals was founded in 2012 and is headquartered in Taichang, China.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $215.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:CNTB
- Website: connectbiopharm.com
- Phone: 0512-53577866
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/connect-biopharmaceuticals-37790 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.